Galapagos changed course earlier this year, announcing it no longer wanted to focus on cell therapy and would seek buyers for this business. After shopping around the assets for months, Galapagos ...

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos The plan would enable the ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U ...